Access cutting-edge sickle cell disease treatment through this clinical trial at a research site in Palo Alto. Study-provided care at no cost to qualified participants.
Access sickle cell disease specialists in Palo Alto at no cost
This study follows strict safety protocols and ethical guidelines
All study-related sickle cell disease treatment provided free
This study is a first-in-human, single-arm, open-label Phase I/II study of nula-cel in approximately 15 participants, diagnosed with severe Sickle Cell Disease. The primary objective is to evaluate safety of the treatment in this patient population, as well as preliminary efficacy and pharmacodynamic data.
Sponsor: Kamau Therapeutics
Check if you qualify for this sickle cell disease clinical trial in Palo Alto, CA
If you're searching for sickle cell disease treatment options in Palo Alto, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Palo Alto research site is actively enrolling participants for this clinical trial. You'll receive care from experienced sickle cell disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.